T1	Participants 91 162	Primary biliary cholangitis (formerly called primary biliary cirrhosis)
T2	Participants 531 641	217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable
T3	Participants 1027 1067	216 patients who underwent randomization
